Table 2.

Cell cycle distribution in lung cancer cells treated with sulindac, Ad-mda 7, or both

TreatmentA549 (%)
H1299 (%)
G1SG2-MG1SG2-M
Untreated control medium68.6 ± 0.726.4 ± 0.216.9 ± 0.1458.8 ± 0.9828.5 ± 0.4112.8 ± 0.49
Control + sulindac 0.125 mmol/L64.8 ± 0.1428.9 ± 0.356.4 ± 0.5666.4 ± 0.4222.3 ± 0.2811.4 ± 0.63
Control + sulindac 0.5 mmol/L75.6 ± 0.1418.5 ± 0.146.0 ± 0.0774.6 ± 1.713.0 ± 1.3412.7 ± 0.42
Ad-mda741.3 ± 0.6331.6 ± 0.6327.2 ± 0.0744.2 ± 0.9813.5 ± 0.742.5 ± 0.77
Ad-mda7 + sulindac 0.125 mmol/L35.6 ± 0.1431.8 ± 0.732.7 ± 0.3646.9 ± 1.214.0 ± 0.2839.2 ± 0.91
Ad-mda7 + sulindac 0.5 mmol/L43.4 ± 0.2142.6 ± 0.0712.3 ± 2.449.2 ± 0.718.4 ± 0.632.4 ± 6.9
Ad-luc73.8 ± 1.517.1 ± 1.97.1 ± 0.6378.3 ± 3.59.8 ± 1.411.9 ± 0.56
Ad-luc + sulindac 0.5 mmol/L70.0 ± 8.118.5 ± 6.311.5 ± 1.670.4 ± 1.59.7 ± 0.3020 ± 0.14
  • NOTE: Cells were treated with PBS, Ad-luc, or Ad-mda7 alone, or in combination with 0.5 mmol/L sulindac for 72 hours followed by FACS analysis. The percentage of cells in each cell cycle phase was determined by analysis of the DNA content histogram. Values are the means of duplicate samples ± SD. Similar results were observed in at least two independent experiments.